Vaccine-Mediated Mechanisms Controlling Francisella tularensis SCHU S4 Growth in a Rat Co-Culture System

Abstract

Francisella tularensis causes the severe disease tularemia. In the present study, the aim was to identify correlates of protection in the rat co-culture model by investigating the immune responses using two vaccine candidates conferring distinct degrees of protection in rat and mouse models. The immune responses were characterized by use of splenocytes from naïve or Live vaccine strain- (LVS) or ∆clpB/∆wbtC-immunized Fischer 344 rats as effectors and bone marrow-derived macrophages infected with the highly virulent strain SCHU S4. A complex immune response was elicited, resulting in cytokine secretion, nitric oxide production, and efficient control of the intracellular bacterial growth. Addition of LVS-immune splenocytes elicited a significantly better control of bacterial growth than ∆clpB/∆wbtC splenocytes. This mirrored the efficacy of the vaccine candidates in the rat model. Lower levels of IFN-γ, TNF, fractalkine, IL-2, and nitrite were present in the co-cultures with ∆clpB/∆wbtC splenocytes than in those with splenocytes from LVS-immunized rats. Nitric oxide was found to be a correlate of protection, since the levels inversely correlated to the degree of protection and inhibition of nitric oxide production completely reversed the growth inhibition of SCHU S4. Overall, the results demonstrate that the co-culture assay with rat-derived cells is a suitable model to identify correlates of protection against highly virulent strains of F. tularensis

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 30, 2020
Source ID
10.3390/pathogens9050338

Entities

People

  • Anders Sjöstedt
  • Carl Gelhaus
  • Helena Lindgren
  • Igor Golovliov
  • Kjell Eneslätt
  • Patrik Rydén
  • Terry Wu

Organizations

  • Defense Threat Reduction Agency

Tags

Fields of Study

  • Biology

Readers

  • Immunology
  • Immunology and Pathology
  • Infectious Disease/Epidemiology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech